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CD8+ T cells are inherently cross-reactive and recognize numerous
peptide antigens in the context of a given major histocompatibility
complex class I (MHCI) molecule via the clonotypically expressed
T cell receptor (TCR). The lineally expressed coreceptor CD8 inter-
acts coordinately with MHCI at a distinct and largely invariant site
to slow the TCR/peptide-MHCI (pMHCI) dissociation rate and enhance
antigen sensitivity. However, this biological effect is not necessarily
uniform, and theoretical models suggest that antigen sensitivity can
be modulated in a differential manner by CD8. We used two intrinsi-
cally controlled systems to determine how the relationship between
the TCR/pMHCI interaction and the pMHCI/CD8 interaction affects the
functional sensitivity of antigen recognition. Our data show that mod-
ulation of the pMHCI/CD8 interaction can reorder the agonist hierar-
chy of peptide ligands across a spectrum of affinities for the TCR.
CD8 coreceptor | pMHCI | T cell activation
CD8+ T cells are critical for protective immunity against in-tracellular pathogens and various tumors. At the molecular
level, activation is triggered by foreign or mutated peptide fragments
presented on the cell surface by major histocompatibility com-
plex class I (MHCI) molecules, which act as ligands for the somatically
rearranged T cell receptor (TCR) and the germline-encoded
coreceptor CD8 (1, 2). The clonotypically expressed TCR con-
fers antigen specificity by interacting with the peptide-binding
platform of MHCI, which comprises the α1 and α2 domains,
whereas the lineally expressed coreceptor CD8 is known to en-
hance antigen sensitivity by interacting primarily with the α3
domain of MHCI (3–7). This latter interaction is biophysically
and spatially independent of peptide-MHCI (pMHCI) engage-
ment via the TCR (8). However, the largely invariant nature of
the pMHCI/CD8 interaction does not necessarily translate into a
uniform gain of function, and theoretical studies have suggested
that antigen sensitivity can be modulated in a differential manner,
potentially altering the agonist hierarchy of peptide ligands for any
given TCR (9–11).
The pMHCI/CD8 interaction slows the dissociation rate of the
TCR/pMHCI interaction (9, 12). Functional sensitivity depends
nonmonotonically on this dissociation rate (13), as long as the
system is limited by MHCI (10, 14, 15). The nature of this re-
lationship implies that functional sensitivity reaches a maximum
at a particular dissociation rate. Strong agonists are relatively
insensitive to modulation of the dissociation rate, because the
curve has a negligible slope in the vicinity of the optimal value. In
contrast, weak agonists are typically characterized by faster dissoci-
ation rates, modulation of which markedly alters functional sensitivity
(16). Accordingly, the pMHCI/CD8 interaction generally acts to in-
crease agonist potency, maximizing the number of peptide ligands
that can be recognized via a given TCR. However, theoretical models
predict that ligands with dissociation rates below or close to the
optimal value will respond differently, amounting to a differen-
tial focusing effect, whereby strong agonists can become less
potent at dissociation rates beyond the optimal value. If opera-
tive in vivo, such an effect could allow individual clonotypes to
focus on salient ligands (9), reconciling the inherent need for
cross-reactivity with the inherent need for specificity (17).
We used two monoclonal systems incorporating biophysically
defined peptide ligands and variants ofMHCI with altered coreceptor-
binding properties to test the differential focusing hypothesis experi-
mentally. In line with earlier predictions, we found that modu-
lation of the pMHCI/CD8 interaction reordered the agonist
hierarchy of peptide ligands recognized via the TCR.
Results
To test the notion that coreceptor-mediated effects can alter ligand
specificity, we determined the extent to which CD8 modulated
functional responses initiated via the MEL5 TCR, which recognizes
the heteroclitic Melan-A epitope ELAGIGILTV26–35/A27L (ELA)
restricted by HLA-A*0201 (abbreviated from hereon as HLA-A2).
Ligand recognition in this system has been characterized previously
using surface plasmon resonance (18, 19). Biophysically defined
peptide ligands, including a weak agonist (3T), the wild-type
epitope (ELA), and a superagonist (FAT), were selected for
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the purposes of this work to introduce a range of TCR/pMHCI
affinities (Table 1). C1R cells expressing HLA-A2 D227K/T228A,
which abrogates the coreceptor interaction (20), wild-type HLA-
A2, HLA-A2 A245V/Kb, which enhances the coreceptor interac-
tion (21), or HLA-A2 Kb, which superenhances the coreceptor
interaction (22), were used in parallel to introduce a range of
pMHCI/CD8 affinities (Table 2). Importantly, surface plasmon
resonance experiments have shown that none of these mutations,
namely D227K/T228A, A245V/Kb, and Kb, affect the TCR/pMHCI
interaction (12, 21).
In preliminary experiments, we quantified CD69 on the surface
of MEL5 TCR+ CD8+ J.RT3-T3.5 cells as a measure of activation
in response to 3T, ELA, or FAT presented in the context of HLA-
A2 D227K/T228A, wild-type HLA-A2, or HLA-A2 A245V/Kb (SI
Appendix, Figs. S1 and S2). Functional sensitivity was determined as
the pEC50 value for each parameter combination (Fig. 1A). In the
absence of a pMHCI/CD8 interaction (HLA-A2 D227K/T228A),
activation was a simple function of TCR/pMHCI affinity (Fig. 1A
and SI Appendix, Figs. S1 and S2). The agonist potencies of 3T and
ELA were enhanced in the context of HLA-A2 and HLA-A2
A245V/Kb relative to HLA-A2 D227K/T228A (Fig. 1A). In con-
trast, the agonist potency of FAT was only marginally enhanced in
the context of HLA-A2 relative to HLA-A2 D227K/T228A and,
consistent with the notion of an optimal activation window, de-
creased slightly in the context of HLA-A2 A245V/Kb relative to
HLA-A2 (Fig. 1A and SI Appendix, Fig. S3A). As a consequence,
the agonist potency of FAT relative to the agonist potency of ELA
was reduced at higher pMHCI/CD8 affinities (Fig. 1B), and in three
of four replicate experiments, ELA was the most potent ligand in
the context of HLA-A2 and HLA-A2 A245V/Kb (Fig. 1 B–E).
To confirm these findings, we quantified the production of
IFN-γ by clonal MEL5 CD8+ T cells in response to 3T, ELA, or
FAT presented in the context of HLA-A2 D227K/T228A, wild-
type HLA-A2, or HLA-A2 Kb (SI Appendix, Figs. S4 and S5).
Functional sensitivity was again determined as the pEC50 value
for each parameter combination (Fig. 2A). The activation data
were largely analogous to those obtained with MEL5 TCR+
CD8+ J.RT3-T3.5 cells. In particular, the agonist potency of
FAT was enhanced in the context of HLA-A2 relative to HLA-
A2 D227K/T228A and decreased slightly in the context of HLA-
A2 Kb relative to HLA-A2 (Fig. 2A and SI Appendix, Fig. S3B),
mirroring the downturn in functional sensitivity observed with
MEL5 TCR+ CD8+ J.RT3-T3.5 cells in the context of HLA-A2
A245V/Kb relative to HLA-A2 (Fig. 1A and SI Appendix, Fig.
S3A). As a consequence, the agonist potency of FAT relative to
the agonist potency of ELA was again reduced at higher pMHCI/
CD8 affinities (Fig. 2B), and in three of four replicate experi-
ments, ELA was the most potent ligand in the context of HLA-
A2 Kb (Fig. 2 B–E).
In further experiments, we quantified the production of IFN-γ
and MIP-1β by clonal MEL5 CD8+ T cells in response to ELA
or 1I, a superagonist characterized for the purposes of this work,
presented in the context of HLA-A2 D227K/T228A, wild-type
HLA-A2, or HLA-A2 Kb (Table 1 and SI Appendix, Fig. S6).
Irrespective of the functional readout, 1I was the more potent
agonist in the context of HLA-A2 D227K/T228A and HLA-A2,
whereas ELA was the more potent agonist in the context of
HLA-A2 Kb, thereby eliminating the possibility of a spurious link
between the observed differential focusing effect and the anchor
residue mutation present in FAT (SI Appendix, Fig. S6).
To confirm these findings in another intrinsically controlled
system, we used a similar approach to determine the extent to
which CD8 modulated functional responses initiated via the
ILA1 TCR, which recognizes the human telomerase reverse
transcriptase epitope ILAKFLHWL540–548 (ILA) restricted by
HLA-A2. Biophysically defined peptide ligands, including a weak
agonist (5Y), the wild-type epitope (ILA), and two superagonists
(3G and 3G8R), were again selected for the purposes of this work
to introduce a range of TCR/pMHCI affinities (SI Appendix, Table
S1). Irrespective of the functional readout, the agonist potencies
of 5Y and ILA were enhanced in the context of HLA-A2 and
HLA-A2 Kb relative to HLA-A2 D227K/T228A, whereas the
agonist potencies of 3G and 3G8R were only marginally en-
hanced in the context of HLA-A2 relative to HLA-A2 D227K/
T228A and decreased slightly in the context of HLA-A2 Kb relative
to HLA-A2 (SI Appendix, Figs. S7 and S8). As a consequence, ILA
was the most potent ligand in the context of HLA-A2 Kb, thereby
validating the general applicability of differential focusing beyond
the idiosyncratic properties of a singular TCR (SI Appendix, Figs.
S7 and S8).
Collectively, these results can be interpreted and understood
in biological terms if two key assumptions are made: 1) func-
tional sensitivity depends nonmonotonically on the TCR/pMHCI
dissociation rate (13); and 2) the pMHCI/CD8 interaction affects
the TCR/pMHCI dissociation rate by an invariant factor, equivalent
to translation on a logarithmic scale (Fig. 3). In this scenario, li-
gands that are recognized poorly in the absence of a pMHCI/CD8
interaction become more potent in the presence of a physiological
pMHCI/CD8 interaction and achieve optimal agonist potency in
the presence of a supraphysiological pMHCI/CD8 interaction,
whereas ligands that are recognized strongly in the absence of a
pMHCI/CD8 interaction straddle an optimum in the presence of
a physiological pMHCI/CD8 interaction and become less potent
in the presence of a supraphysiological pMHCI/CD8 interaction.
Accordingly, the agonist hierarchy of peptide ligands, which is
dictated in isolation by the TCR/pMHCI interaction, can be
reordered as a function of coengagement by CD8.
Discussion
CD8+ T cells are inherently promiscuous and can recognize
more than a million different peptide ligands via the TCR
(23–26). It is well established that CD8 can enhance the func-
tional sensitivity of antigen recognition, but in any given mono-
clonal system, it does not necessarily follow that CD8 will affect
the agonist potency of every cognate ligand in a similar manner.
Indeed, theoretical studies have suggested that the agonist hi-
erarchy of peptide ligands can be modified or even reversed
across a range of pMHCI/CD8 affinities, such that a differential
focusing effect acts to optimize the recognition of particular li-
gands in the context of an individual TCR (9, 10, 15). Our data
provide experimental confirmation of these predictions.
Table 1. TCR/pMHCI dissociation constants and kinetics for
agonists of the MEL5 TCR
MHCI Epitope kon (M
−1s−1) koff (s
−1) KD (μM)
HLA-A2 ELTGIGILTV (3T) ∼1.2 × 104 ∼1 82 ± 4
HLA-A2 ELAGIGILTV (ELA) ∼4.4 × 104 ∼0.75 17 ± 1
HLA-A2 FATGIGIITV (FAT) ∼1.2 × 105 0.36 3 ± 1
HLA-A2 ILAGIGILTV (1I) ∼1.3 × 105 ∼1.3 10.2 ± 0.7*
*Surface plasmon resonance data are shown in SI Appendix, Fig. S6A.
Table 2. pMHCI/CD8 dissociation constants for variants of
HLA-A2
MHCI Mutation KD (μM)
HLA-A2 D227K/T228A MHCI α3 domain >10,000
HLA-A2 WT N/A 137 ± 9.7
HLA-A2 A245V/Kb MHCI α3 domain 27 ± 1
HLA-A2 Kb MHCI α3 domain 11
N/A, not applicable.
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The biological relevance of differential focusing remains un-
known, but hypothetical considerations suggest that such an ef-
fect may be advantageous in vivo, especially if accompanied by
feedback mechanisms that enable the process of specificity ad-
justment to converge on a foreign antigen. Optimal recognition
of a particular agonist in this manner would maximize immune
efficacy during the process of clonal expansion and simulta-
neously minimize the risk of autoimmunity. Affinity maturation
subserves an equivalent function in B cells. In more general terms,
differential focusing also provides a solution to the “Mason para-
dox,” allowing a high degree of immune specificity alongside suf-
ficient coverage of the peptide universe within a relatively small
naive repertoire via the incorporation of degenerate TCRs (17).
Although it remains to be determined how differential focus-
ing could operate in vivo and to what extent this might occur
throughout the lifespan of any given clonotype, elegant studies
have already provided important mechanistic clues. For example,
double-positive thymocytes can transcriptionally down-regulate
CD8 (27), and antigen encounters in the periphery can dynam-
ically modulate clonal responsiveness via the selective internali-
zation of CD8 (28). In addition, coreceptor use can be switched
between the functionally distinct isoforms CD8-αα and CD8-αβ
(29), which are further modifiable via glycosylation (30–32), and
cytokine signals can transcriptionally alter the expression of CD8
(33). All of these processes affect the signaling threshold for
activation via the TCR in a manner akin to affinity variation in
the pMHCI/CD8 interaction (12, 34). Accordingly, functional
sensitivity depends on the kinetics of signalosome development
(9, 10), which is determined by agonist potency and regulated by
CD8 (35).
In line with earlier theoretical predictions, the data presented
here show that agonist potency, quantified in terms of functional
sensitivity, can be differentially modulated across a range of
TCR/pMHCI affinities by CD8. If this phenomenon occurs
in vivo, as suggested by previous mechanistic studies, then immune
reactivity could be focused on individual peptide ligands in the
context of antigen-driven clonal expansions. On the basis of these
collective observations, we propose that specificity adjustment
operates at the level of individual clonotypes to safeguard the host
in the face of an ongoing immune response, simultaneously facili-
tating the targeted delivery of effector functions and mitigating the
risk of bystander damage, which can be triggered by inherently
degenerate and therefore potentially autoreactive TCRs.
Materials and Methods
Cells. MEL5 TCR+ CD8+ J.RT3-T3.5 cells were maintained in Roswell Park
Memorial Institute (RPMI) 1640 medium containing 100 U/mL penicillin,
100 μg/mL streptomycin, 2 mM L-glutamine, and 10% heat-inactivated fetal
calf serum (all from Thermo Fisher Scientific) (R10). Clonal MEL5 and ILA1
CD8+ T cells were maintained in R10 supplemented with 200 IU/mL IL-2 and
25 ng/mL IL-15 (both from PeproTech). The MEL5 TCR is specific for the
heteroclitic HLA-A2–restricted Melan-A epitope ELA (18, 36), and the ILA1
TCR is specific for the HLA-A2–restricted human telomerase reverse tran-
scriptase epitope ILA (37). Human embryonic kidney (HEK) 293 cells were
grown in Dulbecco’s modified Eagle’s medium (Sigma-Aldrich) supplemented
with 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine, 10%
heat-inactivated fetal calf serum, and 10 mM HEPES (all from Thermo Fisher
Scientific). C1R cells expressing comparable levels of HLA-A2 or variants
thereof were generated and maintained as described previously (38).
Peptides. All peptides were synthesized at >95% purity using standard Fmoc
chemistry (BioSynthesis Inc.).
Lentiviruses. The α and β chains of the MEL5 TCR were engineered to contain
mouse constant domains (39) and cloned into a single pSF–Lenti–EF-1α lentiviral
vector (Oxford Genetics) separated by a P2A sequence (Genewiz). The α and β
chains of CD8 were cloned similarly into a single pSF–Lenti–EF-α lentiviral vector
(Oxford Genetics) separated by an internal ribosomal entry site sequence
(Genewiz). HEK 293 cells were cotransfected with the MEL5 TCR or CD8-αβ







































































Fig. 1. CD8 reorders the agonist hierarchy of peptide ligands that induce the expression of CD69. MEL5 TCR+ CD8+ J.RT3-T3.5 cells were activated for 6 h with
C1R cells expressing comparable levels of HLA-A2 D227K/T228A (KO), wild-type HLA-A2 (WT), or HLA-A2 A245V/Kb (VKb) pulsed with various concentrations
of 3T (blue), ELA (black), or FAT (red). Surface expression of CD69 was measured via flow cytometry. (A) Functional sensitivity (pEC50) for each peptide ligand
in the context of each MHCI. Four replicate experiments are shown. The value for 3T in the context of HLA-A2 D227K/T228A was set to zero for graphical
purposes and treated as missing data for statistical purposes. P < 0.0001 for the ligand effect and P < 0.0001 for the MHCI effect (two-way ANOVA with
Tukey’s post hoc test). (B) The agonist potency of FAT relative to the agonist potency of ELA expressed as pEC50
FAT − pEC50ELA, which is equivalent to the
logarithm of the fold difference in functional sensitivity. Four replicate experiments are shown. Horizontal bars indicate median values. *P < 0.05 and **P <
0.01 (one-way ANOVA with Tukey’s post hoc test). (C–E) Representative peptide titration experiment used to calculate the parameters in A and B. Curves were
fitted in Mathematica. All four replicate experiments are shown in SI Appendix, Figs. S1 and S2.
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pCMV-VSV-G using Turbofect Transfection Reagent (Thermo Fisher Scientific).
Lentiviral particles were concentrated using Lenti-X Concentrator (Takara Bio).
Generation of MEL5 TCR+ CD8+ J.RT3-T3.5 Cells. TCR-deficient J.RT3-T3.5 cells
were transduced with MEL5 TCR lentiviral particles and magnetically
enriched using anti-murine TCR-β–PE (clone REA318) in conjunction with
anti-PE MicroBeads (Miltenyi Biotec). MEL5 TCR+ J.RT3-T3.5 cells were then
transduced with CD8-αβ lentiviral particles, and MEL5 TCR+ CD8+ J.RT3-T3.5
cells were flow-purified using an Influx Cell Sorter (BD Biosciences).
Quantification of Activation-Induced CD69. C1R cells expressing comparable
levels of HLA-A2 D227K/T228A, wild-type HLA-A2, or HLA-A2 A245V/Kb were
pulsed for 1 h with various concentrations of the indicated peptides. Cells
were then washed twice with RPMI 1640 medium containing 100 U/mL
penicillin and 100 μg/mL streptomycin and resuspended in R10. Each assay
included 1.5 × 105 peptide-pulsed C1R cells and 5 × 104 MEL5 TCR+ CD8+
J.RT3-T3.5 cells. Unpulsed targets were used as negative controls. Expression
of CD69 on the surface of MEL5 TCR+ CD8+ J.RT3-T3.5 cells was measured
after 6 h using the following directly conjugated monoclonal antibodies:
anti-CD8-α–PE-Cy7 (clone RPA-T8; Thermo Fisher Scientific), anti-CD8-β–
eFluor660 (clone SIDI8BEE; Thermo Fisher Scientific), anti-CD69–BV421 (clone
FN50; BioLegend), and anti-HLA-A2–FITC (clone BB7.2; BioLegend). Nonvia-
ble cells were excluded from the analysis using LIVE/DEAD Fixable Aqua
(Thermo Fisher Scientific). Data were acquired using a NovoCyte Flow
Cytometer (ACEA Biosciences) and analyzed using FlowJo software version
10.6.1 (FlowJo LLC).
Quantification of Activation-Induced IFN-γ and MIP-1β. C1R cells expressing
comparable levels of HLA-A2 D227K/T228A, wild-type HLA-A2, or HLA-A2 Kb
were pulsed for 1 h with various concentrations of the indicated peptides.
Cells were then washed twice with RPMI 1640 medium containing 100 U/mL
penicillin and 100 μg/mL streptomycin and resuspended in R10. Each assay
included 6 × 104 peptide-pulsed C1R cells and 3 × 104 clonal MEL5 or ILA1
CD8+ T cells. Unpulsed targets were used as negative controls. Supernatants
were harvested after 4 h and evaluated for IFN-γ or MIP-1β using enzyme-
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Fig. 2. CD8 reorders the agonist hierarchy of peptide ligands that induce the production of IFN-γ. Clonal MEL5 CD8+ T cells were activated for 4 h with C1R
cells expressing comparable levels of HLA-A2 D227K/T228A (KO), wild-type HLA-A2 (WT), or HLA-A2 Kb (Kb) pulsed with various concentrations of 3T (blue),
ELA (black), or FAT (red). Secretion of IFN-γ was measured using an enzyme-linked immunosorbent assay. (A) Functional sensitivity (pEC50) for each peptide
ligand in the context of each MHCI. Four replicate experiments are shown. Values below the limit of estimation were set to zero for graphical purposes and
treated as missing data for statistical purposes. P = 0.0042 for the ligand effect and P = 0.00069 for the MHCI effect (two-way ANOVA with Tukey’s post hoc
test). (B) The agonist potency of FAT relative to the agonist potency of ELA expressed as pEC50
FAT − pEC50ELA, which is equivalent to the logarithm of the fold
difference in functional sensitivity. Four replicate experiments are shown. Horizontal bars indicate median values. *P < 0.05 (one-way ANOVA with Tukey’s
post hoc test). (C–E) Representative peptide titration experiment used to calculate the parameters in A and B. Curves were fitted in Mathematica. All four


















TCR/pMHCI dissociation rate (logarithmic scale)
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ELTGIGILTV FATGIGIITVELAGIGILTV
Fig. 3. Theoretical interpretation of the differential focusing effect mediated by CD8. Graphical representation of the differential focusing effect based on
two key assumptions: 1) functional sensitivity depends nonmonotonically on the TCR/pMHCI dissociation rate; and 2) the pMHCI/CD8 interaction affects the
TCR/pMHCI dissociation rate by an invariant factor, equivalent to translation on a logarithmic scale (SI Appendix). (A–C) Modulation of the pMHCI/CD8 in-
teraction moves peptide ligands along this curve, altering the agonist hierarchy as a function of the TCR/pMHCI dissociation rate. (D) A hypothetical ultra-
strong pMHCI/CD8 interaction would be expected to reverse the agonist hierarchy from FAT > ELA > 3T to FAT < ELA < 3T.
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Statistics. Functional assay data were processed using simultaneous nonlinear
least squares parameter estimation encoded in Mathematica (23). Functional
sensitivity (pEC50) was expressed as the decimal cologarithm p of the 50%
efficacy concentration (EC50). Assay-derived estimates of pEC50 were treated
as input data for subsequent analyses of variance. Data were analyzed using
a one-way or two-way ANOVA with Tukey’s post hoc test in Mathematica or
Prism software version 8 (GraphPad).
Data Availability. All study data are included in the article and/or SI Appendix.
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